EN DE

EASY BIO,Inc. (353810) Fair Value & Analysis

Consumer Non-Cyclicals · KR · Market cap 202B KRW

EB EASY BIO,Inc. 353810 · KQ
Price6,480 KRW
Fair Value17,633 KRW
Upside+172.1%
Quality63/100
Watch EASY BIO,Inc. for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 6.3% net margin
Moderate debt · generates free cash flow
3.62% dividend yield
Ranks above peers (6/7)
Moderate moat 48/100
Evidence: High Range 12,952 KRW – 49,972 KRW Share as image

Fair value as of: Jul 21, 2026

From 24 valuation models · updated 21 days ago

Fair value updated Jul 21, 2026, revised from 16,375 KRW to 17,633 KRW (+7.7%) since Jun 25, 2026. Share price +4.0% over the past month.

A solid business, screening 172% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (12,952 KRW). The market is more pessimistic than our downside scenario.
  • The model range is unusually wide (12,952 KRW to 49,972 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

8,060 KRW 2,737 KRW Fair Value 17,633 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 2,737 KRW – 8,060 KRW · fair‑value band 12,952 KRW – 49,972 KRW · the 6,480 KRW price screens below the 17,633 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

EASY BIO,Inc. (353810) currently trades at 6,480 KRW, while our model-based Fair Value estimate is 17,633 KRW, implying the stock looks roughly 172.1% undervalued today. The Quality Score stands at 63/100 (solid quality), in the Consumer Non-Cyclicals sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, EASY BIO,Inc. generated revenue of 150B KRW at a net margin of 6.3%. Revenue grew 23.5% year over year. Net debt stands at 91.4B KRW. Fundamentals as of Jul 21, 2026

Our scenario range runs from 12,952 KRW (bear case) to 49,972 KRW (bull case); at 6,480 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 38% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at 7% fair-value upside, at 172%, 353810 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 15,093 KRW 31,705 KRW 59,605 KRW 80
Residual Income 6,529 KRW 8,881 KRW 61,571 KRW 76
Rev-Margin DCF 16,530 KRW 30,669 KRW 60,197 KRW 74
All 24 models by family
DCF Models
FCF DCF 16,028 KRW 25,984 KRW 58,538 KRW 38
Owner Earnings 15,695 KRW 37,083 KRW 83,991 KRW 31
5Y Revenue Exit 14,903 KRW 26,794 KRW 51,751 KRW 39
5Y EBITDA Exit 16,918 KRW 30,869 KRW 58,259 KRW 41
5Y P/E Exit 14,874 KRW 33,489 KRW 58,854 KRW 38
10Y Revenue Exit 14,935 KRW 35,116 KRW 48,583 KRW 36
10Y EBITDA Exit 17,063 KRW 39,557 KRW 79,175 KRW 37
10Y P/E Exit 15,538 KRW 35,053 KRW 67,144 KRW 35
Earnings-Based
Graham-Dodd 6,065 KRW 42,299 KRW 59,361 KRW 54
Lynch FV 21,853 KRW 31,219 KRW 40,585 KRW 50
PEG = 1.0 21,853 KRW 31,219 KRW 40,585 KRW 46
EPV 12,772 KRW 15,067 KRW 17,106 KRW 59
Multiples
P/E Multiple 14,049 KRW 18,731 KRW 23,414 KRW 63
P/S Multiple 11,373 KRW 15,163 KRW 18,954 KRW 58
P/B Multiple 11,373 KRW 15,163 KRW 18,954 KRW 55
EV/EBIT 18,190 KRW 24,330 KRW 30,470 KRW 53
EV/EBITDA 16,464 KRW 22,028 KRW 27,592 KRW 54
EV/Revenue 12,917 KRW 18,551 KRW 24,185 KRW 43
Asset-Based
NCAV (Graham) 1,721 KRW 2,306 KRW 3,442 KRW 50
Growth DCF
Growth DCF 15,093 KRW 31,705 KRW 59,605 KRW 80
Rev-Margin DCF 16,530 KRW 30,669 KRW 60,197 KRW 74
Economic Profit
Residual Income 6,529 KRW 8,881 KRW 61,571 KRW 76
ROIC Compounder 17,164 KRW 27,468 KRW 41,912 KRW 72
Growth Earnings
Growth-Adj P/E 28,584 KRW 40,834 KRW 53,085 KRW 68

Widest divergence: Growth Earnings (40,834 KRW) versus Asset-Based (2,306 KRW). Highest evidence: Growth DCF (80).

Notify me when 353810 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 150B KRW
Revenue growth (YoY) +23.5%
Net margin 6.3%
Return on equity 2,788%
Free cash flow 28.4B KRW FY2025
Operating margin 10.7%
More key figures
Dividend yield 3.6%
EPS growth (YoY) -6.0%
Net debt 91.4B KRW FY2025

Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 63/100

Of which business quality 63 · Market factors (momentum, volatility) 45

Profitability 69
Margins and returns on capital today
Quality Growth 81
Are margins and returns improving?
Cashflow 50
Earnings quality: real cash, not paper profit
Fin. Strength 54
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 43
Calm price path (market factor)
Momentum 41
Price trend over the last 3–12 months (market factor)
52W Momentum 54
Distance to the 52-week high (market factor)
Net Issuance 92
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

EASY BIO,Inc. provides specialized piglet feed and feed additives solutions in South Korea and internationally. The company was founded in 2020 and is based in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

EASY BIO,Inc. reported revenue of 477B KRW in FY2025 versus 129B KRW in FY2021, a compound +38.5%/yr. Reported net income was 27.8B KRW in FY2025, compounding +26.4%/yr from FY2021.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
477B KRW
Latest YoY
+24.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+45.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+40.2%
Revenue +38.5%/yr
FY21 129B KRW
FY22 156B KRW
FY23 165B KRW
FY24 384B KRW
FY25 477B KRW
Net income +26.4%/yr
FY21 10.9B KRW
FY22 9.1B KRW
FY23 15.5B KRW
FY24 19.6B KRW
FY25 27.8B KRW

Watch 353810: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "EASY BIO,Inc. Fair Value". https://www.fairvalue-calculator.com/stock/353810

Peer Group

Food & Tobacco · 19 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 63 · Above median
Fair Value upside +172% · Top 25%
Return on assets 7% · Top 25%
Net margin (TTM) 6% · Top 25%
Operating margin (TTM) 11% · Top 25%
Revenue growth 24% · Top 25%
Debt / equity 0.63× · Higher than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 33
FUTURE 100 · sector 0
PAST 0 · sector 0
HEALTH 69 · sector 94
DIVIDEND 72 · sector 0

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Tobacco

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Food & Tobacco stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
FB FB 49.00 PHP 49.03 PHP +0%
URC URC 61.20 PHP 47.86 PHP -22%
CNPF CNPF 32.50 PHP 64.84 PHP +100%
540743 540743 ₹556.65 ₹616.73 +11%
DNL DNL 3.64 PHP 3.43 PHP -6%
RFM RFM 5.41 PHP 8.87 PHP +64%
AXLM AXLM 2.70 PHP 2.89 PHP +7%
Helixmith Co 084990 3,315 KRW 823.10 KRW -75%
LFM LFM 26.60 PHP 7.12 PHP -73%
MSC Co 009780 6,020 KRW 22,224 KRW +269%

Compare EASY BIO,Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is EASY BIO,Inc. (353810) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of 17,633 KRW versus a price of 6,480 KRW, about +172% (undervalued).
What is the fair value of 353810?
Our model-based fair value for EASY BIO,Inc. is 17,633 KRW (as of Jul 21, 2026), built from audited fundamentals. The current price is 6,480 KRW.
What is the quality score of 353810?
EASY BIO,Inc. has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of EASY BIO,Inc. (353810)?
EASY BIO,Inc. reported trailing-twelve-month revenue of about 150B KRW (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 353810?
The net profit margin of EASY BIO,Inc. is about 6.3%, meaning it keeps roughly 6.3% of revenue as net income. Based on the latest reported figures.
Does EASY BIO,Inc. pay a dividend?
EASY BIO,Inc. currently shows a dividend yield of about 3.62% relative to its recent price (as of Jul 21, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track EASY BIO,Inc. and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.